CEO Buys 168,894 QTREX Shares at $0.71, Signaling Insider Confidence in Respiratory‑Support Growth

Corporate News – Detailed Market Analysis

Ben‑Noon Dagi Shahar, Chief Executive Officer of QTREX, added 168,894 ordinary shares to his personal portfolio on 28 September 2026, paying an average price of $0.71 per share—slightly above the prevailing market level of $0.688. This purchase follows a series of sizable acquisitions made in late August and early September, during which Shahar’s holdings increased from approximately 2.48 million to 3.65 million shares. The latest transaction aligns with QTREX’s 2026‑06 management share‑purchase plan and signals continued optimism regarding the company’s long‑term growth trajectory, even as the share price has fallen 42.86 % over the past year.

1. Market Dynamics and Share Performance

The recent weekly dip of 12.82 % and the 52‑week low of $0.283 indicate significant downside pressure. Analysts attribute this volatility to skepticism around QTREX’s ability to monetize its respiratory‑support platform, which remains in the development stage. Nevertheless, the company’s stock has experienced an unusually high social‑media buzz (up 775 %) and a modestly positive sentiment (+13), suggesting that insider confidence may outpace broader market sentiment.

2. Competitive Positioning

QTREX operates in the respiratory‑support sector, which is currently crowded with firms offering alternative ventilation solutions. Key competitors include:

QTREX’s pipeline focuses on a novel respiratory‑support platform that integrates advanced sensor technology with real‑time data analytics. While the platform has not yet achieved commercial deployment, its potential to reduce hospitalization time and improve patient outcomes could position QTREX favorably against established competitors, provided regulatory approvals are secured.

3. Economic Factors Influencing Valuation

• Capital Allocation: QTREX’s management share‑purchase plan is designed to signal confidence without diluting shareholder value. The plan’s structure (zero‑price purchases for large blocks) allows senior executives to accumulate shares while minimizing cash outlay.
• Regulatory Landscape: The respiratory‑support market is heavily regulated, with the FDA and EMA as primary gatekeepers. Any delays in clearance can materially affect the company’s revenue timelines.
• Supply Chain Considerations: Global shortages of semiconductor components and medical-grade materials have introduced cost volatility. QTREX’s manufacturing strategy, which includes diversified sourcing, mitigates but does not eliminate this risk.

4. Insider Trading Pattern and Strategic Implications

Ben‑Noon Dagi Shahar’s trading history reveals a preference for large, cumulative purchases rather than frequent, small transactions. A notable example occurred on 28 August 2026, when Shahar purchased 550,000 shares at a zero price under the company’s share‑purchase plan. This pattern suggests:

• Strategic Positioning: Accumulating significant block holdings during specific windows indicates an intent to strengthen voting power ahead of potential strategic decisions (e.g., partnerships, capital raises).
• Confidence Signal: Persistent accumulation, even amidst a depressed share price, signals insider conviction that the market undervalues QTREX’s long‑term prospects.

The CEO’s current holding of 3.6 million shares represents approximately 8.4 % of the outstanding shares (51.3 million shares outstanding; market cap $432 million). This sizeable stake underscores a personal belief that the company can translate its research and development efforts into commercially viable products.

5. Outlook for Investors

While Shahar’s recent purchase is a bullish cue, investors should adopt a cautious “wait‑and‑see” stance until the following milestones are achieved:

1. Product Milestones: Completion of pre‑clinical trials and successful transition to early‑phase clinical studies.
2. Regulatory Filings: Submission and approval of Investigational Device Exemptions (IDEs) and eventual clearance from the FDA or EMA.
3. Strategic Partnerships: Announcements of collaborations with established medical device distributors or research institutions.
4. Financial Health: Demonstration of sustainable cash flows and controlled burn rate.

If QTREX can meet these objectives, the share price is likely to recover, potentially validating Shahar’s confidence in the company’s future. Until then, the CEO’s trades provide a subtle yet important signal of internal optimism amid a market that remains ambivalent.

Transaction Summary